Overview

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

Status:
Completed
Trial end date:
2021-08-11
Target enrollment:
0
Participant gender:
Female
Summary
This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments are fezolinetant low dose (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant high dose (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study will compare fezolinetant and placebo after 4 and 12 weeks of dosing. The study will see if fezolinetant reduces the number of hot flashes. And the study will see if fezolinetant reduces the severity of the hot flashes. Women in the study will receive an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants will use this to record their hot flashes. Their record for the 10 days before the start of study treatment will be checked. They can remain in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they will be picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin. The study participants will take study treatment for 52 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors do not know who takes which of the study treatments (fezolinetant low dose, fezolinetant high dose or placebo) during that time. The last 40 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors know which study treatment that study participant takes during that time. Women who take fezolinetant during the first 12 weeks will continue to take the same dose. Women who take placebo during the first 12 weeks will start taking fezolinetant. Their dose will be either low dose or high dose fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants will go to the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. Study participants will complete questionnaires that are about how hot flashes affect their daily life. Study participants who still have their uterus will have the following 2 tests done at the first and last study visits. One of the 2 tests is endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. This test uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Criteria
Inclusion Criteria:

- Subject has a body mass index ≥ 18 kg/m^2 and ≤ 38 kg/m^2.

- Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated
with menopause and confirmed as menopausal per 1 of the following criteria at the
screening visit:

- Spontaneous amenorrhea for ≥ 12 consecutive months

- Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause
(follicle-stimulating hormone [FSH] > 40 IU/L); or

- Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit.

- Within the 10 days prior to randomization, subject must have a minimum average of 7 to
8 moderate to severe hot flashes (HFs) vasomotor symptoms (VMS) per day, or 50 to 60
per week.

- Subject is in good general health as determined on the basis of medical history and
general physical examination, including a bimanual clinical pelvic examination and
clinical breast examination devoid of relevant clinical findings, performed at the
screening visit; hematology and biochemistry parameters, pulse rate and/or blood
pressure and electrocardiogram (ECG) within the reference range for the population
studied, or showing no clinically relevant deviations.

- Subject has documentation of a normal/negative or no clinically significant findings
mammogram (obtained at screening or within the prior 12 months of study enrollment).
Appropriate documentation includes a written report or an electronic report indicating
normal/negative or no clinically significant mammographic findings.

- Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus
and ovaries at screening and at week 52 end of treatment (EOT), and for subjects who
are withdrawn from the study prior to completion, a TVU at the early discontinuation
(ED) visit.

- Subject is willing to undergo an endometrial biopsy at screening and at week 52 (EOT),
for subjects with uterine bleeding, and for subjects who are withdrawn from the study
prior to completion. The endometrial biopsy obtained at screening must be considered
evaluable.

- Subject has documentation of a normal or not clinically significant Papanicolaou (Pap)
test (or equivalent cervical cytology) within the previous 12 months or at screening.

- Subject has a negative urine pregnancy test at screening.

- Subject has a negative serology panel (i.e., negative hepatitis B surface antigen,
negative hepatitis C virus antibody and negative human immunodeficiency virus antibody
screens) at screening.

- Subject agrees not to participate in another interventional study while participating
in the present study.

Exclusion Criteria:

- Subject uses a prohibited therapy (strong or moderate cytochrome P450 1A2 [CYP1A2]
inhibitors, hormone replacement therapy [HRT], hormonal contraceptive or any treatment
for VMS [prescription, over the counter or herbal]) or is not willing to wash out and
discontinue use of such drugs for the full duration of study conduct.

- Subject has known substance abuse or alcohol addiction within 6 months of screening.

- Subject has previous or current history of a malignant tumor, except for basal cell
carcinoma.

- Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80
mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within
the screening period.

- Subjects who do not meet these criteria may be re-assessed after initiation or
review of antihypertensive measures.

- Subjects with a medical history of hypertension can be enrolled once they are
medically clear (stable and compliant).

- Subject has history of severe allergy, hypersensitivity or intolerance to drugs in
general, including the study drug and any of its excipients.

- Subject has an unacceptable result from the TVU assessment at screening (i.e., full
length of endometrial cavity cannot be visualized or presence of a clinically
significant finding).

- Subject has an endometrial biopsy confirming presence of disordered proliferative
endometrium, endometrial hyperplasia, endometrial cancer or other clinically
significant findings at screening.

- Subject has a history within the last 6 months of undiagnosed uterine bleeding.

- Subject has a history of seizures or other convulsive disorders.

- Subject has a medical condition or chronic disease (including history of neurological
[including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary
[e.g., moderate asthma], endocrine or gynecological disease) or malignancy that could
confound interpretation of the study outcome.

- Subject has active liver disease, jaundice or elevated liver aminotransferases
(alanine aminotransferase [ALT] or aspartate aminotransferase [AST]), elevated total
or direct bilirubin, elevated international normalized ratio (INR), or elevated
alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 times
the upper limit of normal (ULN) can be enrolled if total and direct bilirubin are
normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if
cholestatic liver disease is excluded and no cause other than fatty liver is
diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be
enrolled as long as direct bilirubin, hemoglobin and reticulocytes are normal.

- Subject has creatinine > 1.5 × ULN; or estimated glomerular filtration rate (eGFR)
using the Modification of Diet in Renal Disease formula ≤ 59 mL/min per 1.73 m^2 at
screening.

- Subject has a history of suicide attempt or suicidal behavior within the last 12
months or has suicidal ideation within the last 12 months (a response of "yes" to
question 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity
Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening
and at randomization.

- Subject has previously been enrolled in a clinical trial with fezolinetant.

- Subject is participating concurrently in another interventional study or participated
in an interventional study within 28 days prior to screening, or received any
investigational drug within 28 days or within 5 half-lives prior to screening,
whichever is longer.

- Subject is unable or unwilling to complete the study procedures.

- Subject has any condition which makes the subject unsuitable for study participation.

- Subject has had partial or full hysterectomy.